Eloralintide

Overview

Eloralintide is an experimental weight-loss medicine from Eli Lilly, given as a once-weekly shot. It copies amylin, a hormone made alongside insulin that helps you feel full. It is getting attention because a 48-week trial showed about 20% average weight loss at the top dose without using a GLP-1 drug.

How it works

Established for the drug class, proposed for this molecule: natural amylin is released with insulin after meals and acts on amylin receptors (the calcitonin receptor paired with RAMP helper proteins) in the brainstem to increase fullness and slow stomach emptying. Eloralintide is described by Lilly as a long-acting, selective amylin receptor agonist, meaning it is designed to favor amylin receptors rather than also strongly activating the plain calcitonin receptor (unlike cagrilintide). The company believes it lowers calorie intake mainly by increasing satiety. It does not act on GLP-1 receptors.

What research shows

• Phase 2 RCT (n=263 adults with obesity or overweight, no diabetes, 48 weeks): mean weight loss ranged from 9.5% (1 mg) to 20.1% (9 mg) vs 0.4% with placebo (efficacy estimand); all doses beat placebo.
• In the same trial, 57% of people on 9 mg lost at least 20% of body weight; investigators reported that most of the lost weight was fat mass.
• Phase 1 multiple-dose study (12 weeks, n≈100): dose-related weight loss of roughly 2.6% to 11.3%, with mostly mild stomach-related side effects (ADA 2025 data; full paper in Diabetes, Obesity and Metabolism 2026).
• Phase 3 trials started in 2026 (obesity without diabetes, obesity with type 2 diabetes, add-on to weekly incretin therapy); no phase 3 results yet.

Doses studied in people

Investigational drug; doses listed are research doses from one phase 2 trial, not an approved or recommended dose.

Read this first: these are the amounts given to participants in published studies or written on official prescribing labels, reported for reference. They are not recommendations. Trial doses were chosen for specific patients under medical supervision, and a dose that is safe in one person can be harmful in another.

Weekly protocol

How the schedule looks week by week. Each chart says where it comes from: a prescribing label, a clinical trial, or a protocol commonly reported online.

Reference only, not a recommendation. Label and trial schedules were set for specific patients under medical supervision. Use the calculator only to understand the arithmetic.

Vial math

Many research vials hold 5 or 10 mg of powder. This table shows how much ends up in each mark on a U-100 insulin syringe for common amounts of added liquid. It is arithmetic only, not a dose.

More sizes: all vial sizes · How this works: Syringes and units · Reconstitution guide.

Safety

• Phase 2: nausea (about 33%) and fatigue (about 27%) were the most common side effects across eloralintide groups; most were mild to moderate.
• Nausea, diarrhea and vomiting were more frequent at 6 mg and 9 mg; starting at 3 mg and stepping up gave stomach-related rates similar to placebo.
• Serious adverse events were similar to placebo (about 5% in both) and no deaths were reported in phase 2.
• About one-third of weight lost was lean mass according to investigators; long-term safety is unknown because phase 3 trials are ongoing.

Report side effects of any drug or product to the FDA through MedWatch. For a possible poisoning in the US, call Poison Control at 1-800-222-1222.

Legal status

FDA

Investigational; not FDA-approved (phase 3 trials ongoing as of Oct 2026).

Compounding

Not part of any FDA-approved drug and not on the 503A bulk-substances lists, so it is not a lawful compounding ingredient; no FDA statement specific to eloralintide was found.

Sports (WADA)

Not named on the WADA list; as an unapproved drug it falls under S0 (non-approved substances, prohibited at all times). The 2027 list (effective Jan 1, 2027) adds wording that peptides in general fall under S0.

Other

Not a controlled substance.

Rules change often. See Legal status of peptides for how these categories work.

History

Discovered and developed by Eli Lilly under the code LY3841136; a 2025 paper described its path from discovery to early human proof of concept. Phase 1 results were shown at the American Diabetes Association meeting in June 2025. Phase 2 results (48 weeks, 263 adults) were announced and published in The Lancet in November 2025. Lilly began a phase 3 program in 2026, including a roughly 1,980-person trial in people with obesity or overweight without type 2 diabetes (started February 2026) and studies in type 2 diabetes, sleep apnea, and as an add-on to weekly incretin drugs.

Common questions

Related compounds

Sources

1. Billings LK et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: 48-week phase 2 RCT. Lancet 2025 Journal
2. Healio: Novel amylin receptor agonist induces clinically meaningful weight loss (report of Lancet phase 2 results) Journal
3. Eli Lilly press release: eloralintide phase 2 results (Nov 6, 2025; NCT06230523) Regulatory
4. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. Mol Metab 2025 Journal
5. Bhattachar S et al. Eloralintide, a selective, long-acting amylin receptor agonist: phase 1 proof of concept. Diabetes Obes Metab 2026 Journal
6. DelveInsight: Eloralintide phase I data (ADA 2025 summary) Journal
7. ClinicalTrials.gov NCT07321886: Eloralintide in obesity or overweight without type 2 diabetes (phase 3) ClinicalTrials.gov
10. ClinicalTrials.gov NCT07282600: Eloralintide in obesity or overweight with type 2 diabetes ClinicalTrials.gov
11. ClinicalTrials.gov NCT07392190: Eloralintide in persistent obesity during weekly incretin treatment ClinicalTrials.gov
12. EU CTIS 2025-523769-11-00: Eloralintide in obstructive sleep apnea and obesity (ENLIGHTEN-3) ClinicalTrials.gov
8. WADA Prohibited List Regulatory
9. USADA Athlete Advisory: What's new on the 2027 WADA Prohibited List Regulatory